Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Ymmunobio Appoints New Chief Operating Officer

Ymmunobio Accepted into Innosuisse Core Coaching

Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board

FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver Cancer

Ymmunobio Appoints Dr. Caroline Germa to Board of Directors

Ymmunobio Appoints Angela S. Gibbs as Chief Business Officer

Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodies

Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer

Ymmunobio selected by BIO-Europe to participate in its Start-up Spotlight Session

Ymmunobio to Present Pre-Clinical Data at Annual Meeting of the Society for Immunotherapy of Cancer

Ymmunobio Signs Collaboration Agreement with YUMAB

Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH

Ymmunobio AG announces appointment of Dr. Keith Skubitz